Vital Therapies Inc (VTL) Given Consensus Recommendation of “Buy” by Brokerages

Vital Therapies Inc (NASDAQ:VTL) has received a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company.

A number of research analysts recently commented on the stock. William Blair upgraded shares of Vital Therapies from a “market perform” rating to an “outperform” rating in a research note on Monday. BidaskClub upgraded shares of Vital Therapies from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 12th. ValuEngine upgraded shares of Vital Therapies from a “hold” rating to a “buy” rating in a research report on Friday, June 29th. BTIG Research restated a “hold” rating on shares of Vital Therapies in a research report on Monday, May 28th. Finally, Zacks Investment Research upgraded shares of Vital Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, May 12th.

A number of institutional investors have recently bought and sold shares of the business. Northern Trust Corp grew its position in Vital Therapies by 12.0% in the first quarter. Northern Trust Corp now owns 83,688 shares of the company’s stock worth $569,000 after buying an additional 8,993 shares during the last quarter. TD Asset Management Inc. grew its position in Vital Therapies by 50.2% in the second quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock worth $249,000 after buying an additional 12,144 shares during the last quarter. Citigroup Inc. grew its position in Vital Therapies by 1,093.5% in the first quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock worth $108,000 after buying an additional 14,576 shares during the last quarter. Renaissance Technologies LLC grew its position in Vital Therapies by 27.4% during the 4th quarter. Renaissance Technologies LLC now owns 69,300 shares of the company’s stock worth $412,000 after purchasing an additional 14,900 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Vital Therapies by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 192,788 shares of the company’s stock worth $1,147,000 after purchasing an additional 18,050 shares in the last quarter. Hedge funds and other institutional investors own 28.06% of the company’s stock.

NASDAQ VTL opened at $8.55 on Monday. Vital Therapies has a 12 month low of $2.55 and a 12 month high of $9.16.

Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.03. equities research analysts expect that Vital Therapies will post -1.23 earnings per share for the current year.

Vital Therapies Company Profile

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Recommended Story: Google Finance

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply